Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells

Rosalinda Madonna; Christian Cadeddu; Martino Deidda; Paolo Spallarossa; Concetta Zito; Giuseppe Mercuro

doi:10.2174/1389450117666160401125404

Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells

Rosalinda Madonna, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito, Giuseppe Mercuro

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Review article › peer-review

Abstract

Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.

Original language	English
Journal	Current Drug Targets
Volume	17
Issue number	16
DOIs	https://doi.org/10.2174/1389450117666160401125404
Publication status	Published - Jan 1 2016

Keywords

Cardiac stem cells
Chemotherapy-induced cardiotoxicity
Pluripotent stem cells
Preclinical models

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.2174/1389450117666160401125404

Cite this

@article{a6a0f2aa6fca4cda85888b017151535b,

title = "Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells",

abstract = "Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.",

keywords = "Cardiac stem cells, Chemotherapy-induced cardiotoxicity, Pluripotent stem cells, Preclinical models",

author = "Rosalinda Madonna and Christian Cadeddu and Martino Deidda and Paolo Spallarossa and Concetta Zito and Giuseppe Mercuro",

year = "2016",

month = jan,

day = "1",

doi = "10.2174/1389450117666160401125404",

language = "English",

volume = "17",

journal = "Current Drug Targets",

issn = "1389-4501",

publisher = "Bentham Science Publishers B.V.",

number = "16",

}

TY - JOUR

T1 - Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells

AU - Madonna, Rosalinda

AU - Cadeddu, Christian

AU - Deidda, Martino

AU - Spallarossa, Paolo

AU - Zito, Concetta

AU - Mercuro, Giuseppe

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.

AB - Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC)-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.

KW - Cardiac stem cells

KW - Chemotherapy-induced cardiotoxicity

KW - Pluripotent stem cells

KW - Preclinical models

UR - http://www.scopus.com/inward/record.url?scp=84995576478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995576478&partnerID=8YFLogxK

U2 - 10.2174/1389450117666160401125404

DO - 10.2174/1389450117666160401125404

M3 - Review article

C2 - 27033187

AN - SCOPUS:84995576478

VL - 17

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 16

ER -

Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this